{"schema_version":"1.0","type":"article","title":"Lilly Cut Obesity Drug Prices 15% and Grew 39%","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo-en.md","lang":"en","date":"2026-11-02","publish_at":"2026-11-02T08:00:00+08:00","updated_at":"2026-11-02","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Eli Lilly","Novo Nordisk","obesity drugs","Mounjaro","earnings"],"summary":"Lilly's Q3 2026 realised prices fell 15% while volume rose 53%, lifting revenue 39% to $24.40bn and guidance to $91–92bn. Novo Nordisk, facing the same cuts, guides 2026 sales flat to down 6%.","key_points":["Lilly's 2027 revenue guidance, due early 2027, will have a midpoint of at least $100 billion: in Q3 2026 its realised prices fell 15%, volume rose 53% and revenue grew 39% to $24.40 billion.","On October 29, 2026 Lilly raised its 2026 revenue guidance from $85–87 billion to $91–92 billion; Novo Nordisk's August 4, 2026 outlook calls for adjusted sales growth of 0% to minus 6%.","Mounjaro sold $10.72 billion in Q3 2026, up 65%, including $5.7 billion outside the U.S. (up 93%), now larger than its $5.0 billion in U.S. sales."],"facts":[{"claim":"Eli Lilly Q3 2026 revenue","value":24397,"unit":"USD million","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 revenue YoY growth","value":39,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 global volume change","value":53,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 global realised price change","value":-15,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 U.S. revenue","value":15.1,"unit":"USD billion","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 U.S. realised price change","value":-7,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 ex-U.S. realised price change","value":-29,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 ex-U.S. volume change","value":76,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Mounjaro Q3 2026 worldwide revenue","value":10723,"unit":"USD million","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Mounjaro Q3 2026 ex-U.S. revenue","value":5.7,"unit":"USD billion","as_of":"2026-10-29","source":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"claim":"Zepbound Q3 2026 worldwide revenue","value":5352,"unit":"USD million","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Foundayo Q3 2026 revenue","value":184,"unit":"USD million","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 reported gross margin","value":83.9,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly 2026 revenue guidance (raised)","value":"91–92","unit":"USD billion","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Eli Lilly Q3 2026 acquired IPR&D charges","value":4181,"unit":"USD million","as_of":"2026-10-29","source":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"claim":"People filling Lilly prescriptions via Medicare GLP-1 bridge since July 1","value":"more than 500,000","unit":"people","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"claim":"Eli Lilly 2026 one-time revenue items not recurring","value":2,"unit":"USD billion","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"claim":"Mounjaro Q3 2025 worldwide revenue","value":6.52,"unit":"USD billion","as_of":"2025-10-30","source":"https://www.americanpharmaceuticalreview.com/1315-News/622437-Lilly-Delivers-Record-Q3-Results-Raises-Full-Year-Guidance-Amid-R-D-Pipeline-Momentum/"},{"claim":"Wegovy pill Q2 2026 sales","value":3218,"unit":"DKK million","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"Novo Nordisk 2026 adjusted sales growth outlook","value":"0 to -6","unit":"% (CER)","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"U.S. injectable Wegovy Q2 2026 sales change (CER)","value":-22,"unit":"%","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"Wegovy U.S. list price cut from 2027-01-01","value":50,"unit":"% (approx.)","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"Wegovy pill cumulative U.S. prescriptions","value":5,"unit":"million prescriptions (more than)","as_of":"2026-08-04","source":"https://glp1-us.com/news/2026-08-04-novo-q2-wegovy-pill-5m-prescriptions/"},{"claim":"Foundayo FDA approval date","value":"2026-04-01","unit":"date","as_of":"2026-04-01","source":"https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/"},{"claim":"Eli Lilly ex-U.S. incretin market share Q3 2026","value":58,"unit":"% (approx.)","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"}],"sections":["01 | Prices fell 15%. How did revenue rise 39%?","02 | Where the new patients came from","03 | Novo is winning the pill race and losing the overall ledger","04 | What it takes to reach $100 billion","References"],"references":[{"title":"Lilly reports third-quarter 2026 financial results, raises full-year guidance","source":"Eli Lilly","date":"2026-10-29","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"title":"Lilly Q3 earnings: revenue rises 39% to $24.4B (full release and tables","source":"Stock Titan","date":"2026-10-29","url":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"title":"Eli Lilly (LLY) Q3 2026 Earnings Call Transcript","source":"The Motley Fool","date":"2026-10-29","url":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"title":"Lilly Delivers Record Q3 Results, Raises Full-Year Guidance (Q3 2025","source":"American Pharmaceutical Review","date":"2025-10-30","url":"https://www.americanpharmaceuticalreview.com/1315-News/622437-Lilly-Delivers-Record-Q3-Results-Raises-Full-Year-Guidance-Amid-R-D-Pipeline-Momentum/"},{"title":"Financial report for the period 1 January 2026 to 30 June 2026","source":"Novo Nordisk","date":"2026-08-04","url":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"title":"Novo Nordisk Q2: Wegovy pill tops 5M US prescriptions","source":"GLP-1 US","date":"2026-08-04","url":"https://glp1-us.com/news/2026-08-04-novo-q2-wegovy-pill-5m-prescriptions/"},{"title":"FDA approves Lilly obesity pill, triggering battle with Novo Nordisk","source":"BioPharma Dive","date":"2026-04-01","url":"https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/"},{"title":"Hanmi's half-price obesity shot takes on Mounjaro","source":"Drugnews","date":"2026-10-20","url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.html"},{"title":"Lilly's two-drug obesity bet","source":"Drugnews","date":"2026-10-14","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html"},{"title":"Lilly's tirzepatide growth","source":"Drugnews","date":"2026-05-08","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html"}],"images":[],"cover_image":"https://drugnews.com.tw/assets/articles/lilly-q3-2026-glp1-price-cut-volume-novo-en/default-brand.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-02）。Lilly Cut Obesity Drug Prices 15% and Grew 39%。https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}